Blood Podcast by American Society of Hematology
American Society of Hematology
カテゴリー: 科学／医学
マイリストに追加
最後のエピソードを聴く:
In this week's episode, Blood editor Dr. Laurie Sehn interviews authors Drs. Lorenzo Falchi and Robert Levy on their latest papers published in Blood Journal. Dr. Falchi discusses his work on an open-label, multicenter phase 1b/2 study evaluating fixed-duration epcoritamab with rituximab and lenalidomide in 108 patients with relapsed or refractory follicular lymphoma. Dr. Levy shares his work on demonstrating that in vivo expansion of Tregs in recipients prior to transplant is possible by activating TNFRSF25 (also known as death receptor 3) in combination with low-dose interleukin-2 in preclinical models. Both papers showed impressive and promising results for the treatment of lymphoma and GVHD.
Featured Articles
- Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma
- Pre-transplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues ameliorating GVHD post-HSCT
前のエピソード
-
354 - Fixed-Duration Epcoritamab Combination Therapy for Relapsed or Refractory Follicular Lymphoma and Pre-Transplant Strategies for GVHD post-HSCTThu, 27 Nov 2025
-
353 - Advancing Blood Disorder Treatments Through Precision TherapeuticsThu, 20 Nov 2025
-
352 - New Research: Mitochondrial DNA in TRALI and Venetoclax-Obinituzumab in CLL TrialsThu, 13 Nov 2025
-
351 - Bispecific Antibodies in Aggressive B-Cell Lymphoma: Real-World Insights and Future DirectionsThu, 06 Nov 2025
-
350 - Review Series on Follicular LymphomaThu, 30 Oct 2025
-
349 - Breakthroughs in Multiple Myeloma Treatment and Von Willebrand Disease MechanismsThu, 23 Oct 2025
-
348 - Spotlight on Acute Myeloid LeukemiaThu, 16 Oct 2025
-
347 - Busulfan-melphalan conditioning in newly diagnosed, transplant-eligible multiple myeloma; and use of spatial transcriptomics to probe the three-dimensional properties of multiple myeloma bone marrow microenvironmentsTue, 14 Oct 2025
-
346 - How I Treat Wiskott-Alrich syndromeThu, 02 Oct 2025
-
345 - Use of Marstacimab for Prophylaxis in hemophilia A and B; matched-donor allogeneic CD19 CAR-T in adult B-ALL; a new prognostic index for T-cell cutaneous lymphomasThu, 02 Oct 2025
-
344 - Epstein-Barr virus genomic variants in human disease states, somatic GATA1 mutations and leukemia in Down syndrome, and new definitions for high-risk multiple myelomaThu, 25 Sep 2025
-
343 - Review Series on Acute Lymphoblastic Leukemia (ALL)Thu, 18 Sep 2025
-
342 - Azacitidine holds promise in VEXAS syndrome; a step forward in precision blood matching; identifying a new vulnerability in TP53-mutated AMLThu, 18 Sep 2025
-
341 - Diffuse large B-cell lymphoma’s long-term effects on immune profiles, plasminogen activation and prevention of venous thromboembolism, and PARP inhibitors in hematological malignancies carrying epigenetic mutationsThu, 11 Sep 2025
-
340 - “Ironing out” Tet2-mutant HSPCs; A CAR-T “license to kill” in T cell leukemia/lymphoma; insights on cHL genetics, through the lens of ctDNAThu, 04 Sep 2025
-
339 - Targeting NPM1 in AML with a menin inhibitor; in primates, a CD137 ADC eliminates acute GVHDThu, 28 Aug 2025
-
338 - How I Treat Series on Iron Overload in Hematologic DisordersThu, 28 Aug 2025
-
337 - Early prediction of follicular lymphoma patients with poor survival; immune hotspots in aplastic anemia; role of allo-transplant for Hodgkin lymphoma in the checkpoint inhibitor eraThu, 21 Aug 2025
-
336 - Exogenous CD19 stimulation in B-cell acute lymphoblastic leukemia treated with CD19 CAR T-cell therapy, sequential rapid immune-assay in heparin-induced thrombocytopenia diagnosis, and new survival prediction models for chronic myelomonocytic leukemiaTue, 19 Aug 2025
-
335 - How I Treat series on Acute Myeloid LeukemiaThu, 14 Aug 2025
-
334 - Daratumumab maintenance in newly-diagnosed, transplant-eligible multiple myeloma; the role of neutrophils in myeloproliferative neoplasms; and novel genetic loci associated with the risk of heavy menstrual bleedingThu, 07 Aug 2025
-
333 - Hematopoietic stem cells with enhanced transplantability, ruxolitinib for refractory macrophage activation syndrome, and magrolimab in newly diagnosed acute myeloid leukemiaThu, 31 Jul 2025
-
332 - A JAK inhibitor for CRS and ICANS prevention; ChAdOx1-platelet interactions and post-vaccination arterial thrombosis; lineage switch, an emerging mechanism of leukemia relapseThu, 24 Jul 2025
-
331 - Ruxolitinib plus dexamethasone in newly diagnosed adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors in sickle cell disease; and clinical characteristics of patients with low von Willebrand factorMon, 21 Jul 2025
-
330 - Review series on mantle cell lymphomaThu, 17 Jul 2025
-
329 - Rapid, high-sensitivity ADAMTS13 assays for TTP; combination CD38/PD-1 blockade in extranodal NK/T-cell lymphoma; a “zombie enzyme” in CREBBP-mutant lymphomasThu, 10 Jul 2025
-
328 - A novel mouse model of sickle cell SC disease; multiple myeloma induction therapy with isatuximab, carfilzomib, lenalidomide, and dexamethasone; and splicing factor mutations in myelodysplastic syndromesThu, 03 Jul 2025
-
327 - An AI model for transplant risk in myelofibrosis; preventing priapism in men with sickle cell anemia; hallmarks of T cell exhaustion absent in newly diagnosed MMThu, 26 Jun 2025
-
326 - Social determinants of health and access to allogeneic hematopoietic cell transplantation, megakaryocyte growth factor receptor-based pretransplant conditioning for ex vivo autologous gene therapy, and novel protein biomarkers for risk stratification in aMon, 23 Jun 2025
-
325 - Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsetsThu, 19 Jun 2025
-
324 - A key role for T-cell TET3 in chronic GVHD; a BTK inhibitor for ITP; co-inhibition of pre-TCR and IL-7R pathways in a T-ALL patient subsetThu, 12 Jun 2025
-
323 - Special Episode: Eliminating the Need for Sequential Confirmation of Response in Multiple MyelomaTue, 10 Jun 2025
-
322 - How I Treat Series on Geriatric HematologyThu, 05 Jun 2025
-
321 - Single cell multi-omic analysis of leukemia stem cells, cyclophosphamide for non-immune effector cell-associated neurotoxicity, and glycosylation as a mediator of von Willebrand factor clearanceThu, 05 Jun 2025
-
320 - New insights on PU.1-mutated agammaglobulinemia; venetoclax-based induction therapy in younger AML patients; the link between ABO Blood groups and risk of future VTEThu, 29 May 2025
-
319 - How I Treat Transfusion Medicine (part 2)Thu, 22 May 2025
-
318 - Clonal hematopoiesis in frequent blood donors, immune microenvironment and bispecific antibody response in diffuse large B-cell lymphoma, and blinatumomab as part of early consolidation therapy in CD19-positive Ph-negative B-cell acute lymphoblastic lymphThu, 22 May 2025
-
317 - How I Treat Transfusion Medicine (part 1)Thu, 15 May 2025
-
316 - Discontinuing lenalidomide maintenance in MM; congenital neutropenia syndrome linked to COPZ1 mutations; low GVHD rates with ruxolitinib after allogeneic HCTThu, 15 May 2025
-
315 - Measurable residual disease and maintenance therapy in acute myeloid leukemia (AML), stemness and chemotherapy resistance in AML, and effects of babesiosis on red blood cells in sickle cell diseaseThu, 08 May 2025
-
314 - Uniquely programmed blood stem cells in the human lung; inclusive molecular classifier for DLBCL; new insights on NETs in the liver vasculatureThu, 01 May 2025
-
313 - Phosphoseryl-tRNA kinase inhibition in acute myeloid leukemia (AML), APOE gene variants and post-hematopoietic stem cell transplant outcomes in AML, and the role of chronic inflammation in sickle cell cardiomyopathyThu, 24 Apr 2025
-
312 - How I Treat Myeloproliferative NeoplasmsThu, 17 Apr 2025
-
311 - The decline of transplant for relapsed myeloma; DDAVP response in bleeding disorders; dual DOT1L/EZH2 targeting in DLBCLThu, 17 Apr 2025
-
310 - Interleukin-1 signaling pathways in myelodysplastic syndromes, the immune checkpoint regulator VISTA as a target in graft-vs-host disease, and epcoritamab plus chemotherapy in transplant-ineligible relapsed/refractory diffuse large B-cell lymphomaThu, 10 Apr 2025
-
309 - Aging platelets shift to proinflammatory function; Odronextamab bispecific antibody therapy after CAR T in DLBCL; prizlon-cel, a novel bispecific CAR T, in B-NHLThu, 03 Apr 2025
-
308 - Blood Bonus Episode: What is a Blood group?Mon, 31 Mar 2025
-
307 - Itacitinib in haploidentical hematopoietic cell transplantation, diagnosis and management of purpura fulminans, and lack of evidence for sickle cell crisis-associated mortality in individuals with sickle cell traitThu, 27 Mar 2025
-
306 - Time-limited triplet therapy in relapsed/refractory CLL; patient-reported outcomes in chronic GVHD-related sclerosis; myeloid bias mechanisms in hematopoiesisThu, 20 Mar 2025
-
305 - Azacitidine plus venetoclax in high-risk myelodysplastic syndromes, post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia (B-ALL), and inotuzumab ozogamicin resistance in B-ALLThu, 13 Mar 2025
どのくらいのエピソード
5
